378 related articles for article (PubMed ID: 34018687)
1. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
Nogara PA; Omage FB; Bolzan GR; Delgado CP; Aschner M; Orian L; Teixeira Rocha JB
Mol Inform; 2021 Aug; 40(8):e2100028. PubMed ID: 34018687
[TBL] [Abstract][Full Text] [Related]
2. Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals.
Sun LY; Chen C; Su J; Li JQ; Jiang Z; Gao H; Chigan JZ; Ding HH; Zhai L; Yang KW
Bioorg Chem; 2021 Jul; 112():104889. PubMed ID: 33915460
[TBL] [Abstract][Full Text] [Related]
3. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
[TBL] [Abstract][Full Text] [Related]
4. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.
Weglarz-Tomczak E; Tomczak JM; Talma M; Burda-Grabowska M; Giurg M; Brul S
Sci Rep; 2021 Feb; 11(1):3640. PubMed ID: 33574416
[TBL] [Abstract][Full Text] [Related]
5. Computational analysis of the interactions between Ebselen and derivatives with the active site of the main protease from SARS-CoV-2.
Rieder GS; Nogara PA; Omage FB; Duarte T; Dalla Corte CL; da Rocha JBT
Comput Biol Chem; 2023 Dec; 107():107956. PubMed ID: 37748316
[TBL] [Abstract][Full Text] [Related]
6. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine.
Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954
[TBL] [Abstract][Full Text] [Related]
7. The Se-S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study.
Parise A; Romeo I; Russo N; Marino T
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575955
[TBL] [Abstract][Full Text] [Related]
8. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.
Amporndanai K; Meng X; Shang W; Jin Z; Rogers M; Zhao Y; Rao Z; Liu ZJ; Yang H; Zhang L; O'Neill PM; Samar Hasnain S
Nat Commun; 2021 May; 12(1):3061. PubMed ID: 34031399
[TBL] [Abstract][Full Text] [Related]
9. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
10.
Alesawy MS; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
Molecules; 2021 Oct; 26(21):. PubMed ID: 34771004
[TBL] [Abstract][Full Text] [Related]
11. Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease.
Thun-Hohenstein STD; Suits TF; Malla TR; Tumber A; Brewitz L; Choudhry H; Salah E; Schofield CJ
ChemMedChem; 2022 Feb; 17(4):e202100582. PubMed ID: 34850566
[TBL] [Abstract][Full Text] [Related]
12. Exploring Cannabinoids as Potential Inhibitors of SARS-CoV-2 Papain-like Protease: Insights from Computational Analysis and Molecular Dynamics Simulations.
Holmes J; Islam SM; Milligan KA
Viruses; 2024 May; 16(6):. PubMed ID: 38932170
[TBL] [Abstract][Full Text] [Related]
13. Identification of potent COVID-19 main protease inhibitors by loading of favipiravir on Mg
Al-Shuaeeb RAA; Abd El-Mageed HR; Ahmed SA; Mohamed HS; Hamza ZS; Rafi MO; Rahman MS
J Biomol Struct Dyn; 2023; 41(21):11437-11449. PubMed ID: 36591698
[TBL] [Abstract][Full Text] [Related]
14. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
[TBL] [Abstract][Full Text] [Related]
15. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
Shan H; Liu J; Shen J; Dai J; Xu G; Lu K; Han C; Wang Y; Xu X; Tong Y; Xiang H; Ai Z; Zhuang G; Hu J; Zhang Z; Li Y; Pan L; Tan L
Cell Chem Biol; 2021 Jun; 28(6):855-865.e9. PubMed ID: 33979649
[TBL] [Abstract][Full Text] [Related]
16. Unraveling antiviral efficacy of multifunctional immunomodulatory triterpenoids against SARS-COV-2 targeting main protease and papain-like protease.
Choudhary S; Nehul S; Singh A; Panda PK; Kumar P; Sharma GK; Tomar S
IUBMB Life; 2024 May; 76(5):228-241. PubMed ID: 38059400
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease.
Menéndez CA; Byléhn F; Perez-Lemus GR; Alvarado W; de Pablo JJ
Sci Adv; 2020 Sep; 6(37):. PubMed ID: 32917717
[TBL] [Abstract][Full Text] [Related]
18. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
Amin SA; Banerjee S; Gayen S; Jha T
Eur J Med Chem; 2021 Apr; 215():113294. PubMed ID: 33618158
[TBL] [Abstract][Full Text] [Related]
19.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
20. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL
Zmudzinski M; Rut W; Olech K; Granda J; Giurg M; Burda-Grabowska M; Kaleta R; Zgarbova M; Kasprzyk R; Zhang L; Sun X; Lv Z; Nayak D; Kesik-Brodacka M; Olsen SK; Weber J; Hilgenfeld R; Jemielity J; Drag M
Sci Rep; 2023 Jun; 13(1):9161. PubMed ID: 37280236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
